Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
